Compare HTCR & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTCR | QNRX |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 10.1M |
| IPO Year | 2022 | N/A |
| Metric | HTCR | QNRX |
|---|---|---|
| Price | $0.43 | $12.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 193.6K | ★ 1.1M |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | ★ 29.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,189,136.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $5.01 |
| 52 Week High | $3.38 | $41.80 |
| Indicator | HTCR | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 43.58 |
| Support Level | $0.42 | $10.50 |
| Resistance Level | $0.48 | $15.45 |
| Average True Range (ATR) | 0.04 | 2.79 |
| MACD | 0.00 | -0.90 |
| Stochastic Oscillator | 13.40 | 17.04 |
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.